|
|
305 Chipeta Way
Salt Lake City, UT 84108 United States
phone:(801) 214-7800
fax:(801) 214-7992
|
|
| Symbol |
EP |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.myriadpharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Biotechnology company focused on developing and commercializing novel therapies for cancer |
|
| Management |
| Adrian N. Hobden Ph.D., President, Chief Executive Officer and Director; Wayne Laslie, Chief Operating Officer; Robert Lollini, Chief Financial Officer and Treasurer; Andrew Gibbs J.D., Vice President, General Counsel and Secretary; Patrick M. Burke Ph.D., Vice President, Corporate and Business Development; Robert Carlson Ph.D., Vice President, Head of Research; Andrea Kendell, Vice President, Finance and Human Resources; Gary Mather D.V.M., Ph.D., DABT, Vice President, Head of Development; Kenton H. Zavitz Ph.D., Senior Director, Clinical Affairs |
| |
|
|
|
|
|
|
|
| Keywords |
| cancer, brain cancer, glioblastoma, skin cancer, melanoma, hiv, aids |
|
|
|
| Description |
|
Myrexis, Inc. is a biotechnology company discovering, developing and commercializing novel therapies for the treatment of cancer. Our pipeline includes clinical and pre-clinical product candidates with distinct mechanisms of action and novel chemical structures that have the potential to be first-in-class and/or best-in-class therapeutics.
The discovery and development of each of our drug candidates has been guided by a unique understanding of the genetic causes of human diseases, the genetic factors that may cause drug side effects, drug interactions, and drug metabolism. Our extensive experience in human genetics, protein-protein interaction technology and chemical proteomic drug discovery has allowed identification of novel drug targets and accelerated progression from chemical lead compounds to investigational drug candidates. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
